Kassem Bourgi, MD

Bio

Dr. Bourgi is an assistant professor of Medicine and physician-scientist in the Division of Infectious Diseases. He received his medical degree from the American University of Beirut before completing his internal medicine residency and serving as a chief resident at Henry Ford Wayne State University. Dr. Bourgi then completed his infectious diseases and HIV fellowship at Vanderbilt University and joined the faculty at IU in 2018.

His research focuses on studying the metabolic complications of HIV and long-term use of antiretroviral therapy through observational cohort studies of adults with HIV. He is also interested in studying the association between some of the antiretroviral therapies with weight gain and investigating the underlying mechanism. Additionally, Dr. Bourgi’s research focuses on understanding the association between HIV-related mental health and inflammation, cardiovascular and metabolic outcomes in persons with HIV.

Key Publications

Bourgi K, Ofner S, Musick B, Griffith B, Diero L, Wools-Kaloustian K, Yiannoutsos CT, Gupta SK. Weight Gain among Treatment-naïve Persons with HIV Receiving. Dolutegravir in Kenya. Journal of Acquired Immune Deficiency Syndrome. 2022 Dec 15;91(5):490-6. PubMed ID: 36126175

Bourgi K, Kundu S, Stewart JC, So-Armah K, Freiberg M, Gupta SK. Associations of HIV and Depression with Incident Diabetes Mellitus: Veterans Aging Cohort Study. Clinical Infectious Diseases 2022. DOI: 10.1093/cid/ciac085. PubMed ID: 35134838

Rebeiro PF, Jenkins CA, Bian A, Lake JE, Bourgi K, et al. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships with Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons with Human Immunodeficiency Virus in the United States and Canada. Clinical Infectious Diseases:2021;73(7):e2234-e2242. . DOI: 10.1093/cid/ciaa1403. PubMed ID: 32936919

Leonard MA, Cindi Z, Bradford Y, Bourgi K, Koethe J, et al.  Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. Clinical Infectious Diseases:2021;73(7):e2153-e2163. . DOI: 10.1093/cid/ciaa1219. PubMed ID: 32829410

Bourgi K, Jenkins CA, Rebeiro PF, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc 2020;23(4):e25484. DOI: 10.1002/jia2.25484. PubMed ID: 32294337

Bourgi K, Rebeiro PF, Turner M, et al. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clinical Infectious Diseases 2020. 70(7):1267-1274. DOI: 10.1093/cid/ciz407. PubMed ID: 31100116

Bourgi K, Wanjalla C, Koethe JR. Inflammation and Metabolic Complications in HIV. Current HIV/AIDS Reports 2018;15(5):371-381. DOI: 10.1007/s11904-018-0411-2. PubMed ID: 30058057